Apellis Pharmaceuticals (NASDAQ:APLS) Stock Rating Reaffirmed by HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday, Benzinga reports. They presently have a $92.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 84.52% from the company’s previous close.

Several other analysts also recently commented on APLS. The Goldman Sachs Group lifted their target price on shares of Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a report on Tuesday, January 9th. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a report on Tuesday, February 6th. UBS Group upped their price objective on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Oppenheimer upped their price objective on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a research report on Thursday. Three research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Trading Up 4.0 %

Shares of APLS stock opened at $49.86 on Friday. The firm has a fifty day moving average of $57.84 and a 200-day moving average of $57.35. The company has a debt-to-equity ratio of 0.48, a current ratio of 3.10 and a quick ratio of 2.50. Apellis Pharmaceuticals has a 12-month low of $19.83 and a 12-month high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. During the same quarter last year, the firm earned ($1.50) earnings per share. The firm’s revenue for the quarter was up 545.9% compared to the same quarter last year. On average, analysts predict that Apellis Pharmaceuticals will post -1.34 EPS for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, General Counsel David O. Watson sold 781 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the transaction, the general counsel now owns 103,390 shares in the company, valued at approximately $7,006,740.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, General Counsel David O. Watson sold 781 shares of the stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $67.77, for a total value of $52,928.37. Following the completion of the sale, the general counsel now directly owns 103,390 shares of the company’s stock, valued at approximately $7,006,740.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Nur Nicholson sold 835 shares of the stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $64.14, for a total transaction of $53,556.90. Following the sale, the insider now directly owns 67,507 shares of the company’s stock, valued at $4,329,898.98. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 381,011 shares of company stock worth $23,463,657. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

A number of institutional investors have recently bought and sold shares of APLS. Jennison Associates LLC increased its stake in Apellis Pharmaceuticals by 79.8% in the third quarter. Jennison Associates LLC now owns 3,542,209 shares of the company’s stock worth $134,746,000 after purchasing an additional 1,571,606 shares during the period. Assenagon Asset Management S.A. increased its stake in shares of Apellis Pharmaceuticals by 109.6% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after buying an additional 1,121,497 shares during the period. Norges Bank purchased a new position in shares of Apellis Pharmaceuticals during the fourth quarter valued at $56,640,000. Price T Rowe Associates Inc. MD increased its stake in shares of Apellis Pharmaceuticals by 38.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after buying an additional 677,098 shares during the period. Finally, Polar Capital Holdings Plc increased its stake in shares of Apellis Pharmaceuticals by 126.6% during the third quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after buying an additional 588,875 shares during the period. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).